Immunome Inc.
IMNM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001472012
In the last 90 days, Immunome Inc. insiders filed 0 open-market purchases and 7 sales; 202 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Immunome Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 24 | 28 | +4 |
| Shares | 2.39M | 2.10M | −292.0K (−12.2%) |
| Value | $10.7M | $4.85M | −$5.89M (−54.9%) |
New holders (6)
Institutions that held Immunome Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 22,064 | $48.5K | 0.00% |
| Natixis | 11,000 | $24.3K | 0.00% |
| MB, Levis & Associates, LLC | 2,373 | $5.24K | 0.00% |
| Tower Research Capital LLC (TRC) | 2,358 | $5.00K | 0.00% |
| Farther Finance Advisors, LLC | 100 | $221 | 0.00% |
| Bank of America Corp | 11 | $24 | 0.00% |
Sold out (2)
Institutions that held Immunome Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Neuberger Berman Group LLC | 19,444 | $86.0K |
| BNP Paribas Arbitrage, SA | 67 | $297 |